Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled subcutaneous immunotherapy with modified Parietaria judaica pollen extract
2006-005871-17Phase 3Completed
- Sponsor
- LETI Pharma
- Start
- May 2007
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of depigmented polymerized Parietaria judaica pollen extract in allergic rhinoconjunctivitis (ARC) and allergic asthma (2 arms), sponsored by LETI Pharma. Primary endpoint: Primary symptom score during pollen season. Started May 2007; status: completed.
02
Drugs
depigmented polymerized Parietaria judaica pollen extract
03
Conditions
allergic rhinoconjunctivitis (ARC)allergic asthma
Beyond the preview
Go deeper on 2006-005871-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005871-17.